Table 1

Different diagnoses and stages within the study group and the proportion of patients with cancer cachexia (types 1–3; see Methods)
Type of cancer
 N patients
 Of these cachectic
 I/II1,2 or related stages
 Of these cachectic
 III/IV1,2 or related stages
 Of these cachechtic
 No data about stage
 n female
 Of these cachectic
 n male
 Of these cachectic
Lymphoma1
 202 (40)
 35 (17.3)
 57+
 9 (15.8)
 61+
 22 (36.1)
 16+
 84
 18 (21.4)
 118
 17 (14.4)
Colorectal2
 84 (16)
 23 (27.4)
 9
 3 (33.3)
 71
 19 (26.8)
 4
 33
 7 (21.2)
 51
 16 (31.4)
Leukaemia3
 58 (11)
 7 (12.1)
 *
*
*
 22
 4 (18.2)
 36
 3 (8.3)
Other2 Gastrointestinal
 39 (8)
 15 (38.5)
 4
 1 (25)
 21
 8 (38.1)
 14
 8
 3 (37.5)
 31
 12 (38.7)
Lung2
 36 (7)
 9 (25)
 6
 1 (16.7)
 27
 8 (29.6)
 3
 9
 3 (33.3)
 27
 6 (22.2)
Breast2
 32 (6)
 4 (12.5)
 17
 2 (11.8)
 9
 2 (22.2)
 6
 32
 4 (12.5)
 0
Leukaemia-early stages3,4
 20 (4)
 5 (25)
 *
*
*
 13
 2 (15.4)
 7
 3 (42.9)
Prostate*
 4 (1)
 1 (25)
 *
*
*

4
 1 (25)
Others*
 34 (7)
 8 (23.5)
 *
*
*
 13
 5 (38.5)
 21
 3 (14.3)
Total
 509
 107 (21)
 *
 *
 *
 *
 *
 214
 46 (21.5)
 295
 61 (20.7)

Numbers in parentheses denote the particular percentage.

1Lymphoma subgroups according to WHO (2001) and Ann Arbor classifications.

+The 24 patients with CLL (classification of Binet) and the 44 patients with multiple myeloma (classification of Durie and Salmon) were excluded.

2UICC classification was used for colorectal and other gastrointestinal tumors, breast and lung cancer.

3The different classifications for leucaemia and the leukaemia-early stages could not be used for these groups.

4Patients with myelodysplastic syndromes (MDS) or myeloproliferative syndromes (MPD).

*The classifications for these tumour types could not be used for subgrouping.

Knoll et al. BMC Cancer 2008 8:85   doi:10.1186/1471-2407-8-85